Clinical Trial Update: Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study [Phase 4]

View source ↗

Summary

Pfizer's Phase 4 pilot study evaluating dalteparin for prophylaxis of venous thromboembolism in primary care was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Venous Thromboembolism

Drugs mentioned

• Dalteparin (dalteparin)

Snippet

Sponsor: Pfizer | Conditions: Thromboembolism, Deep Vein Thrombosis | Phase 4 | Status: TERMINATED